Safety of new oral anticoagulant drugs: A perspective

Therapeutic Advances in Drug Safety

Volumn 5, Issue 1, 2014, Pages 8-20

  Vílchez, Juan Antonio ^a,b   Gallego, Pilar ^a,c   Lip, Gregory Y h ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

apixaban; bleeding; dabigatran; new oral anticoagulants; rivaroxaban

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; FRESH FROZEN PLASMA; PROTHROMBIN; PROTHROMBIN COMPLEX;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; DRUG OVERDOSE; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEVERE RENAL IMPAIRMENT; VENOUS THROMBOEMBOLISM;

EID: 84898845794     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613507945     Document Type: Review

References (69)

1. Albertsen I. Larsen T. Rasmussen L. Overvad T. Lip G. (2012) Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. Drugs 72: 1755–1764.
2. Apostolakis S. Sullivan R. Olshansky B. Lip G. (2013) Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT2R2 (sex female, age less than 60, medical history, treatment strategy [rhythm control], tobacco use [doubled], race [doubled] score. Chest 9 May (Epub ahead of print).
3. Baumann Kreuziger L. Morton C. Dries D. (2012) New anticoagulants: a concise review. J Trauma Acute Care Surg 73: 983–992.
4. Buller H. Prins M. Lensin A. Decousus H. Jacobson B. Minar E. (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287–1297.
5. Clave A. Fazilleau F. Dumser D. Lacroix J. (2012) Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case–control study in 70 patients. Orthop Traumatol Surg Res 98: 484–490.
6. Cohen A. Spiro T. Buller H. Haskell L. Hu D. Hull R. (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368: 513–523.
7. Connolly S. Eikelboom J. Joyner C. Diener H. Hart R. Golitsyn S. (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806–817.
8. Connolly S. Ezekowitz M. Yusuf S. Eikelboom J. Oldgren J. Parekh A. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139–1151.
9. De Caterina R. (2009) The current role of anticoagulants in cardiovascular medicine. J Cardiovasc Med (Hagerstown) 10: 595–604.
10. Douketis J. (2010) Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 16: 3436–3441.
11. Dumkow L. Voss J. Peters M. Jennings D. (2012) Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 69: 1646–1650.
12. Eerenberg E. Kamphuisen P. Sijpkens M. Meijers J. Buller H. Levi M. (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124: 1573–1579.
13. Eikelboom J. Wallentin L. Connolly S. Ezekowitz M. Healey J. Oldgren J. (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123: 2363–2372.
14. Eriksson B. Friedman R. (2009) Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost 15(Suppl. 1): 25S–31S.
15. Eriksson B. Quinlan D. Weitz J. (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48: 1–22.
16. Fukuda T. Honda Y. Kamisato C. Morishima Y. Shibano T. (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107: 253–259.
17. Gallego P. Roldan V. Lip G. (2013) Conventional and new oral anticoagulants in the treatment of chest disease and its complications. Am J Respir Crit Care Med 188: 413–421.
18. Geerts W. Bergqvist D. Pineo G. Heit J. Samama C. Lassen M. (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133: 381S-453S.
19. Go A. Fang M. Udaltsova N. Chang Y. Pomernacki N. Borowsky L. (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119: 1363–1369.
20. Godier A. Miclot A. Le B. Durand M. Fischer A. Emmerich J. (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116: 94–102.
21. Granger C. Alexander J. McMurray J. Lopes R. Hylek E. Hanna M. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992.
22. Healey J. Eikelboom J. Douketis J. Wallentin L. Oldgren J. Yang S. (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 126: 343–348.
23. Huisman M. Lip G. Diener H. Brueckmann M. van Ryn J. Clemens A. (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107: 838–847.
24. Jover E. Roldan V. Gallego P. Hernandez-Romero D. Valdes M. Vicente V. (2012) Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) 65: 627–633.
25. Kearon C. Kahn S. Agnelli G. Goldhaber S. Raskob G. Comerota A. (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133: 454S-545S.
26. Khadzhynov D. Wagner F. Formella S. Wiegert E. Moschetti V. Slowinski T. (2013) Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 109: 596–605.
27. Kirchhof P. Lip G. Van Gelder I. Bax J. Hylek E. Kaab S. (2012) Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options – a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 14: 8–27.
28. Komocsi A. Vorobcsuk A. Kehl D. Aradi D. (2012) Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172: 1537–1545.
29. Kyrle P. Eichinger S. (2012) Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 108: 1061–1064.
30. Larsen T. Rasmussen L. Skjoth F. Due K. Callreus T. Rosenzweig M. (2013) Efficacy and safety of dabigatran etexilate and warfarin in ‘real world– patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 61: 2264–2273.
31. Levi M. Eerenberg E. Kamphuisen P. (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9: 1705–1712.
32. Levi M. Eerenberg E. Lowenberg E. Kamphuisen P. (2010) Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 68: 68–76.
33. Lindhoff-Last E. Samama M. Ortel T. Weitz J. Spiro T. (2010) Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 32: 673–679.
34. Lip G. Andreotti F. Fauchier L. Huber K. Hylek E. Knight E. (2011) Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 106: 997–1011.
35. Lip G. Larsen T. Skjoth F. Rasmussen L. (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60: 738–746.
36. Lu G. Deguzman F. Hollenbach S. Karbarz M. Abe K. Lee G. (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19: 446–451.
37. Mani H. Hesse C. Stratmann G. Lindhoff-Last E. (2011) Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 106: 156–164.
38. Marlu R. Hodaj E. Paris A. Albaladejo P. Crackowski J. Pernod G. (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108: 217–224.
39. Miesbach W. Seifried E. (2012) New direct oral anticoagulants–current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 108: 625–632.
40. Miller C. Grandi S. Shimony A. Filion K. Eisenberg M. (2012) Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110: 453–460.
41. Ogata K. Mendell-Harary J. Tachibana M. Masumoto H. Oguma T. Kojima M. (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50: 743–753.
42. Oldgren J. Wallentin L. Alexander J. James S. Jonelid B. Steg G. (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34: 1670–1680.
43. Patel M. Mahaffey K. Garg J. Pan G. Singer D. Hacke W. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–891.
44. Pavord S. Myers B. (2011) Bleeding and thrombotic complications of kidney disease. Blood Rev 25: 271–278.
45. Pengo V. Crippa L. Falanga A. Finazzi G. Marongiu F. Palareti G. (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 106: 868–876.
46. Perez A. Eraso L. Merli G. (2013) Implications of new anticoagulants in primary practice. Int J Clin Pract 67: 139–156.
47. Pisters R. Lane D. Nieuwlaat R. de Vos C. Crijns H. Lip G. (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138: 1093–1100.
48. Poulsen B. Grove E. Husted S. (2012) New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 72: 1739–1753.
49. ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159: 340–347.
50. Samama M. Guinet C. (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49: 761–772.
51. Schiele F. van Ryn J. Canada K. Newsome C. Sepulveda E. Park J. (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121: 3554–3562.
52. Siegal D. Yudin J. Kaatz S. Douketis J. Lim W. Spyropoulos A. (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126: 1630–1639.
53. Soliman E. Prineas R. Go A. Xie D. Lash J. Rahman M. (2010) Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 159: 1102–1107.
54. Spyropoulos A. (2005) Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep 4: 405–413.
55. Spyropoulos A. Douketis J. (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120: 2954–2962.
56. Stangier J. Rathgen K. Stahle H. Gansser D. Roth W. (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292–303.
57. Tsu L. Dager W. (2013) Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes. Ann Pharmacother 47: 573–577.
58. Turpie A. Kreutz R. Llau J. Norrving B. Haas S. (2012) Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 108: 876–886.
59. Turun S. Banghua L. Yuan Y. Zhenhui L. Ying N. Jin C. (2011) A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res 127: 525–534.
60. Van de Werf F. Brueckmann M. Connolly S. Friedman J. Granger C. Hartter S. (2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 163: 931–937.
61. van Ryn J. Stangier J. Haertter S. Liesenfeld K. Wienen W. Feuring M. (2010) Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116–1127.
62. Wallentin L. Lopes R. Hanna M. Thomas L. Hellkamp A. Nepal S. (2013) Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127: 2166–2176.
63. Wallentin L. Yusuf S. Ezekowitz M. Alings M. Flather M. Franzosi M. (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376: 975–983.
64. Warkentin T. Margetts P. Connolly S. Lamy A. Ricci C. Eikelboom J. (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119: 2172–2174.
65. Watson J. Whiteside G. Perry C. (2011) Apixaban: first global approval. Drugs 71: 2079–2089.
66. Weitz J. Quinlan D. Eikelboom J. (2012) Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 126: 2428–2432.
67. Wojcik C. Schymik M. Cure E. (2009) Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2: 217–225.
68. Wong P. Pinto D. Zhang D. (2011) Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 31: 478–492.
69. Zhou W. Schwarting S. Illanes S. Liesz A. Middelhoff M. Zorn M. (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42: 3594–3599.